Case Study: Pfizer achieves 10x antibody throughput and centralized end-to-end R&D with Genedata Biologics (Genedata)

Pfizer Builds on the Genedata Biopharma E2E Workflow Platform

Pfizer, a global biopharma leader, needed to centralize and align large‑molecule R&D workflows after data and teams were fragmented across sites. With more than 200 scientists at six locations and a failed in‑house approach, Pfizer evaluated commercial options and selected Genedata’s enterprise platform—primarily Genedata Biologics—to serve as a single backbone for biologics discovery and development.

Genedata implemented Genedata Biologics (and later Genedata Bioprocess) as an out‑of‑the‑box, extensible COTS solution integrated with Pfizer’s IT and lab automation, enabling custom Pfizer applications and seamless data flow. The Genedata deployment now supports 250+ users in 15 groups across 6 sites and 200+ projects (including >900,000 clones, 28,000 lead molecules and 900 cell lines), cut errors from spreadsheet handoffs, provided real‑time centralized data, and increased antibody-to‑full‑IgG conversion throughput by up to 10×.

Pfizer

Will Somers

Vice President Global Biotherapeutic Technologies